UB Paderborn / Katalog / Suche / in CDI

1 – 14 von 14

Sortiert nach

Pericyte coverage decreases invasion of tumour cells into blood vessels in prostate cancer xenografts

Prostate cancer and prostatic diseases, 2009-03, Vol.12 (1), p.41-46

2009

Volltextzugriff (PDF)

1065 Detection of AR-V7 in circulating tumour cells before ADT is a negative prognostic marker in castration-naïve men with metastatic prostate cancer

European urology supplements : official journal of the European Association of Urology, 2016-03, Vol.15 (3), p.e1065-e1065

2016

Volltextzugriff (PDF)

Circulating tumor cells as liquid biopsies of skeletal metastases

European urology supplements : official journal of the European Association of Urology, 2016-12, Vol.15 (13), p.e1637-e1637

2016

Volltextzugriff (PDF)

740 Growth Factor Midkine is Associated With Castration-resistant Prostate Cancer and Neuroendocrine Differentiation

European journal of cancer (1990), 2012-07, Vol.48, p.S176-S176

2012

Volltextzugriff (PDF)

Transition of an androgen-dependent human prostate cancer cell line into an androgen-independent subline is associated with increased angiogenesis

The Prostate, 2005-03, Vol.62 (4), p.364-373

2005

Volltextzugriff (PDF)

Prevalence and risk factors of angina pectoris and its association with coronary atherosclerosis in a general population, a cross-sectional study

European heart journal, 2022-10, Vol.43 (Supplement_2)

2022

Volltextzugriff (PDF)

P061 - Circulating tumor cells as liquid biopsies of skeletal metastases

European urology supplements : official journal of the European Association of Urology, 2016-12, Vol.15 (13), p.e1637-e1637

2016

Volltextzugriff (PDF)

Reply to Carlos G. Wambier and Gerard J. Nau’s Letter to the Editor re: Karin Welén, Ebba Rosendal, Magnus Gisslén, et al. A Phase 2 Trial of the Effect of Antiandrogen Therapy on COVID-19 Outcome: No Evidence of Benefit, Supported by Epidemiology and In Vitro Data. Eur Urol. 2022;81:285–93. Positive Effects of Enzalutamide for Hospitalized COVID-19 Patients: Still No Positive Effect of Enzalutamide for Hospitalized COVID-19 Patients

European urology, 2022-06, Vol.81 (6), p.e143-e144

2022

Volltextzugriff (PDF)

Reply to Carlos G. Wambier and Gerard J. Nau’s Letter to the Editor re: Karin Welén, Ebba Rosendal, Magnus Gisslén, et al. A Phase 2 Trial of the Effect of Antiandrogen Therapy on COVID-19 Outcome: No Evidence of Benefit, Supported by Epidemiology and In Vitro Data. Eur Urol. 2022;81:285–93. Positive Effects of Enzalutamide for Hospitalized COVID-19 Patients

European urology, 2022-06, Vol.81 (6), p.e143-e144

2022

Volltextzugriff (PDF)

Reply to Carlos G. Wambier and Gerard J. Nau's Letter to the Editor re: Karin Welén, Ebba Rosendal, Magnus Gisslén, et al. A Phase 2 Trial of the Effect of Antiandrogen Therapy on COVID-19 Outcome: No Evidence of Benefit, Supported by Epidemiology and In Vitro Data. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2021.12.013. Positive Effects of Enzalutamide for Hospitalized COVID-19 Patients: Still No Positive Effect of Enzalutamide for Hospitalized COVID-19 Patients

European urology, 2022, Vol.81 (6)

2022

Volltextzugriff (PDF)

Re: Chen Dong, Sung-Lang Chen, and Wen-Wei Sung’s Letter to the Editor re: Karin Welén, Ebba Rosendal, Magnus Gisslén, et al. A Phase 2 Trial of the Effect of Antiandrogen Therapy on COVID-19 Outcome: No Evidence of Benefit, Supported by Epidemiology and In Vitro Data. Eur Urol. 2022;81:285–93

European urology, 2022-05, Vol.81 (5), p.e124-e125

2022

Volltextzugriff (PDF)

Architectural Support for Global Smart Spaces

Lecture notes in computer science, 2003, p.153-164

2003

Volltextzugriff (PDF)

1 – 14 von 14

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(11)
Mit Volltextzugriff
(14)

Publikationsform

Artikel
(13)
Tagungsberichte
(1)

Sprache

Englisch
(14)
Japanisch
(1)

Erscheinungsjahr

n.n

Thema

Science & Technology
(7)
Humans
(6)
Life Sciences & Biomedicine
(6)
Urology & Nephrology
(5)
Male
(4)
Androgen Antagonists - Therapeutic Use
(3)
Covid-19
(3)
Covid-19 - Drug Therapy
(3)
Infectious Medicine
(3)
Infektionsmedicin
(3)
Antiandrogen
(2)
Benzamides
(2)
Clinical Medicine
(2)
Clinical Trials, Phase Ii As Topic
(2)
Covid-19 - Diagnosis
(2)
Enzalutamide
(2)
Female
(2)
Klinisk Medicin
(2)
Letter To The Editor
(2)
Medical And Health Sciences
(2)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Pericyte coverage decreases invasion of tumour cells into blood vessels in prostate cancer xenografts

1065 Detection of AR-V7 in circulating tumour cells before ADT is a negative prognostic marker in castration-naïve men with metastatic prostate cancer

Circulating tumor cells as liquid biopsies of skeletal metastases

740 Growth Factor Midkine is Associated With Castration-resistant Prostate Cancer and Neuroendocrine Differentiation

Transition of an androgen-dependent human prostate cancer cell line into an androgen-independent subline is associated with increased angiogenesis

Prevalence and risk factors of angina pectoris and its association with coronary atherosclerosis in a general population, a cross-sectional study

P061 - Circulating tumor cells as liquid biopsies of skeletal metastases

COVIDENZA - A prospective, multicenter, randomized PHASE II clinical trial of enzalutamide treatment to decrease the morbidity in patients with Corona virus disease 2019 (COVID-19): a structured summary of a study protocol for a randomised controlled trial

A Phase 2 Trial of the Effect of Antiandrogen Therapy on COVID-19 Outcome: No Evidence of Benefit, Supported by Epidemiology and In Vitro Data

Re: Chen Dong, Sung-Lang Chen, and Wen-Wei Sung’s Letter to the Editor re: Karin Welén, Ebba Rosendal, Magnus Gisslén, et al. A Phase 2 Trial of the Effect of Antiandrogen Therapy on COVID-19 Outcome: No Evidence of Benefit, Supported by Epidemiology and In Vitro Data. Eur Urol. 2022;81:285–93

Architectural Support for Global Smart Spaces

Suchergebnisse filtern